Focus: Labcorp is a large-scale contract research organization (CRO) with 70,000 employees generating $12.2B in revenue, providing clinical trial services, laboratory testing, and drug development support to the pharmaceutical industry.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
4 recent layoff filings (12 mo) — 354 affected
Source: state DOL filings via Big Local News
No open roles listed right now. Follow Labcorp to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Labcorp
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Labcorp's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
8-K Filing: ILLUMINA, INC. (ILMN) (CIK 0001110803) — EX-99.1
EX-99.1
8-K Filing: Onconetix, Inc. (ONCO) (CIK 0001782107) — PRESS RELEASE, DATED MARCH 23, 2026
PRESS RELEASE, DATED MARCH 23, 2026
8-K Filing: MODIV INDUSTRIAL, INC. (MDV, MDV-PA) (CIK 0001645873) — EX-99.2
EX-99.2
8-K Filing: MIDDLEBY Corp (MIDD) (CIK 0000769520) — EX-99.1
EX-99.1
8-K Filing: COMMUNITY HEALTH SYSTEMS INC (CYH) (CIK 0001108109) — EX-2.1
EX-2.1
8-K Filing: OPKO HEALTH, INC. (OPK) (CIK 0000944809) — EX-99.1
EX-99.1
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Source: state DOL filings, aggregated via Big Local News
No visible compliance red flags or recent layoff announcements, but the 68% net income collapse warrants monitoring for potential restructuring announcements in upcoming quarters.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo